Risk factor
Very high price volatility
Profitability factor
Favourable analyst view
About
Orexo AB (publ) operates as a specialist pharmaceutical company, dedicated to the research, development, and commercialization of both traditional medications and cutting-edge digital therapeutics. Its reach extends across key markets, including the United States, Europe, and the United Kingdom. Its portfolio of currently available treatments includes Zubsolv, provided in tablet form, which assists in the management of opioid dependence; Abstral, which addresses breakthrough pain episodes experienced by cancer patients; and Edluar, prescribed for temporary insomnia. The company's robust development pipeline features several innovative compounds: OX124 and OX125, designed for naloxone and nalmefene rescue situations respectively; OX640, targeting acute allergic reactions; and OX338, a sublingual tablet formulation of ketorolac intended for moderate to severe pain relief. Additionally, Orexo is progressing the OX-MPI program, which aims to treat microvascular conditions linked to chronic inflammatory diseases. Complementing its pharmaceutical offerings, Orexo also provides digital therapies such as deprexis, for managing mild to severe depression; vorvida, addressing alcohol use disorder; and modia, tailored for opioid use disorder. Founded in 1994, Orexo AB (publ) maintains its headquarters in Uppsala, Sweden.
Company Valuation
From both historical and forecast perspectives, the stock is fairly priced compared to similar stocks. In particular, the stock is undervalued on P/FCF.
Target Price
The average target price of ORX.ST is 29 and suggests 47% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to increa